Eyck, A.

reimbursement health policy growth reimbursement policy condition health insurers growth hormone hormone drug use patient schedule dutch insurance insurer indication speci stakeholder bene fit package policy makers board guideline prescription cholesterol clopidogrel medicine measure therapy analysis micro-level data niezen practice medication netherland regulation number 39–50 database treatment criteria specialist statin effect maker thiazolidinedione physician schedule 2 assessment requirement level group effectiveness health insurance board health insurance company volume fi ve cases change tnf -␣ blockers ficient study restriction disease erasmus mc regime health care outcome ef ficient macro-level data addition schedule 2. table fi gures package etanercept reimbursement measure category committee blocker protocol objective